Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Impact of Telephone Follow-up in Patient's Health-related Quality of Life That Use Warfarin

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03125668
Recruitment Status : Unknown
Verified April 2017 by Rafaela de Oliveira Manzato, University of Sao Paulo.
Recruitment status was:  Recruiting
First Posted : April 24, 2017
Last Update Posted : April 24, 2017
Sponsor:
Information provided by (Responsible Party):
Rafaela de Oliveira Manzato, University of Sao Paulo

Brief Summary:
The purpose of this study is to test an educational program with telephone follow-up to improve health-related quality of life (HRQoL), treatment adherence, and reduce anxiety and depression symptoms in patients who are starting oral anticoagulants (OA).

Condition or disease Intervention/treatment Phase
Quality of Life Warfarin Health Education Patient Compliance Behavioral: Educational Program Behavioral: Telephone follow-up Behavioral: Face to face counseling Not Applicable

Detailed Description:

Randomized controlled trial (RCT) at two Brazilian public hospitals, one in Ribeirão Preto and another one in Américo Brasiliense, state of São Paulo, Brazil.

Both groups will receive the educational program (Power Point®Slides, booklets and orientation) at the hospitalization. After the hospital discharge, the intervention group will receive the telephone follow-up (five calls for six months: 1st call in one week and the others calls month by month until six months) and two face to face counseling (1st meeting in three months and the 2nd meeting in six months). The control group just receive the same face to face counseling (1st meeting in three months and the 2nd meeting in six months) after the hospital discharge.

The educational program consist in information about the use of Warfarin and approach the specific topics in Power Point®Slides: Physiology: Definition of oral anticoagulants, mechanisms of action and clinical indication; Medication: Dose, time, storage and duration of therapy; Monitoring: Meaning of International Normalized Ratio (INR) , collection period and doctor's appointments; Other medications: Drug interactions and those considered "natural"; Feeding: Eating foods rich in K vitamin and fats; Alcoholic beverage: Care about alcohol , and if it occurs, does not stop the Oral Anticoagulants; Gestation: Necessity to start IV anticoagulants; Activities: In physical, domestic or work activities to use protective measures; Health treatment: Warn about OA to other professional and take the card of INR values; Travels: On trips take the OA and be programmed to the realization of INR out of their units; Signs /Symptoms: Report underdose (thrombus formation) and overdose (bleeding), seek health care.

After the orientations with Power Point®Slides, the patients receive one booklet with the same informations and the researcher answer any questions that patients have about the anticoagulation therapy.

In this moment (at hospitalization) the researcher also collects the data about symptoms of anxiety and depression using the validated questionnaire.

During the telephone calls the researcher talk with the patient about the topics that were approach in the educational intervention and motivate the patient to follow the recommendations for they have a successful treatment.

In the face to face counseling (three and six months after hospital discharge) the researcher collect the data about anxiety and depression again, health-related quality of life and adverse events related to oral anticoagulation therapy.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 46 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Supportive Care
Official Title: Impact of Telephone Follow-up in Patient's Health-related Quality of Life During the First Six Months of Warfarin Use: Randomized Clinical Trial
Actual Study Start Date : October 1, 2015
Estimated Primary Completion Date : August 30, 2017
Estimated Study Completion Date : August 30, 2017

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Intervention Group
At the hospitalization, patients receive the educational program (Power Point®Slides, booklets and orientation) about the use of warfarin. After hospital discharge they receive a telephone follow-up (five calls) and two Face to face counseling.
Behavioral: Educational Program
At the hospitalization, patients receive the educational program with Power Point®Slides, booklets and orientation about the use of warfarin.

Behavioral: Telephone follow-up

After hospital discharge they receive a telephone follow-up (five calls for six months: 1st call in one week and the others calls month by month until six months).

During the telephone calls the researcher talk with the patient about the topics that were approach in the educational intervention and motivate the patient to follow the recommendations for they have a successful treatment.


Behavioral: Face to face counseling
They receive two face to face counseling (1st meeting in three months and the 2nd meeting in six months after hospital discharge). In the face to face counseling the researcher collect the data about anxiety and depression again, health-related quality of life and adverse events related to oral anticoagulation therapy.

Active Comparator: Control Group
At the hospitalization, patients receive the educational program (Power Point®Slides, booklets and orientation) about the use of warfarin. After hospital discharge they receive two face to face counseling.
Behavioral: Educational Program
At the hospitalization, patients receive the educational program with Power Point®Slides, booklets and orientation about the use of warfarin.

Behavioral: Face to face counseling
They receive two face to face counseling (1st meeting in three months and the 2nd meeting in six months after hospital discharge). In the face to face counseling the researcher collect the data about anxiety and depression again, health-related quality of life and adverse events related to oral anticoagulation therapy.




Primary Outcome Measures :
  1. Change in Health-Related Quality of Life [ Time Frame: Three and six months after hospital discharge ]
    The Duke Anticoagulation Satisfaction Scale (DASS) was developed by Samsa et al. (2004) and validated for the Brazilian population by Pelegrino et al. (2011). The scale have 25 items divided in three domains: Limitation (9 items); Hassles and burdens (8 items); Psychological Impacts (8 items). All items have seven response categories: "not at all", "a little", "somewhat", "moderately", "quite a bit", "a lot", and "very much". Possible range: 25 to 175 and lower scores, indicated better Health-Related Quality of Life.


Secondary Outcome Measures :
  1. Change in Symptoms of Anxiety and Depression [ Time Frame: At baseline, Three and six months after hospital discharge. ]
    The questionnaire "Hospital Anxiety and Depression Scale (HADS)" was developed by Zigmond and Snaith (1983) and validated and adapted to Portuguese by Botega et al. (1995). The HADS contains 14 multiple choice questions, divided into two subscales: anxiety and depression (composed of seven items each).This questionnaire will be used to collect the data at baseline and at six months.

  2. Adherence [ Time Frame: INR values during the six months follow-up ]
    Patient adherence to oral anticoagulation therapy will be assessed by the INR (International Normalized Ratio) stability that will be calculated by the percentage of time patients remain within the measurement range using the number of INRs within the therapeutic range, divided by the number of INRs collected.

  3. Assessment and frequency of adverse events related to Warfarin [ Time Frame: Three and six months after hospital discharge ]
    Three questions developed by the authors about adverse events related to Warfarin.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age over 18 years;
  • Both genders;
  • To start the use of Warfarin for the first time during the current hospitalization;
  • To have a phone.

Exclusion Criteria:

  • To start the Oral Anticoagulation Therapy with another oral anticoagulant;
  • To start the Warfarin for surgical procedures;
  • To have visual or hearing impairments;
  • Don't have cognitive conditions* to answer the questions of data collection instruments (measured by adapted questions from Pfiefer (1975);
  • To have a cancer diagnosis.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03125668


Contacts
Layout table for location contacts
Contact: Rafaela O Manzato, PhD Student +5517996025036 rafamanzato@hotmail.com

Locations
Layout table for location information
Brazil
Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo Recruiting
Ribeirao Preto, São Paulo, Brazil, 14040902
Contact: Rafaela O Manzato, PhD student    +5517996025036    rafamanzato@hotmail.com   
Sponsors and Collaborators
University of Sao Paulo
Investigators
Layout table for investigator information
Study Chair: Rosana S Dantas, PhD University of São Paulo at Ribeirão Preto College of Nursing

Layout table for additonal information
Responsible Party: Rafaela de Oliveira Manzato, Principal Investigator, University of Sao Paulo
ClinicalTrials.gov Identifier: NCT03125668     History of Changes
Other Study ID Numbers: 38736914.1.0000.5393
First Posted: April 24, 2017    Key Record Dates
Last Update Posted: April 24, 2017
Last Verified: April 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Warfarin
Anticoagulants